Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

被引：0
|
作者：
P. G. Corrie
W. Qian
B. Basu
J. W. Valle
S. Falk
C. lwuji
H. Wasan
D. Palmer
M. Scott-Brown
J. Wadsley
S. Arif
J. Bridgewater
D. Propper
R. Gillmore
A. Gopinathan
R. Skells
P. Bundi
R. Brais
K. Dalchau
L. Bax
A. Chhabra
A. Machin
A. Dayim
K. McAdam
S. Cummins
L. Wall
R. Ellis
A. Anthoney
J. Evans
Y. T. Ma
C. Isherwood
A. Neesse
D. Tuveson
D. I. Jodrell
机构：
[1] Cambridge University Hospitals NHS Foundation Trust (Addenbrooke’s Hospital),Gastroenterology and Gastrointestinal Cancer Clinic
[2] Cancer Research UK—Cambridge Institute,undefined
[3] University of Cambridge,undefined
[4] University of Manchester and The Christie NHS Foundation Trust,undefined
[5] Bristol Haematology and Oncology Centre,undefined
[6] Leicester Royal Infirmary,undefined
[7] Hammersmith Hospital,undefined
[8] Imperial College,undefined
[9] Clatterbridge Cancer Centre,undefined
[10] University Hospital Coventry and Warwickshire,undefined
[11] Weston Park Hospital,undefined
[12] Velindre Cancer Centre,undefined
[13] UCL Cancer Institute,undefined
[14] Barts Cancer Institute,undefined
[15] The Royal Free Hospital,undefined
[16] Peterborough City Hospital,undefined
[17] Royal Surrey County Hospital,undefined
[18] Western General Hospital,undefined
[19] Royal Cornwall Hospitals,undefined
[20] St. James’s University Hospitals,undefined
[21] Beatson West of Scotland Cancer Centre,undefined
[22] University of Glasgow,undefined
[23] Queen Elizabeth Hospital,undefined
[24] University of Göttingen,undefined
[25] Cold Spring Harbor Laboratory,undefined
来源：
British Journal of Cancer | 2020年 / 122卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1760 / 1768
页数：8
相关论文
共 50 条
  • [11] Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma, a retrospective cohort
    Wu, Hongyang
    Huang, Nana
    Zhao, Chenchen
    Hu, Xueyang
    Da, Liangshan
    Huang, Wei
    Shen, Yuanyuan
    Xiong, Fuxing
    Zhang, Congjun
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [12] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [13] Updated results of biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer
    Kokkali, S.
    Drizou, M.
    Tripodaki, E.
    Stefanou, D.
    Magou, E.
    Zylis, D.
    Kapiris, M.
    Nasi, D.
    Georganta, C.
    Ardavanis, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [14] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [15] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
    Cartwright, Thomas H.
    Parisi, Monika
    Espirito, Janet L.
    Wilson, Thomas
    Pelletier, Corey
    Patel, Manish
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [16] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
    Braiteh, Fadi
    Patel, Manish B.
    Parisi, Monika
    Ni, Quanhong
    Park, Siyeon
    Faria, Claudio
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 141 - 148
  • [17] Third -line re -treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel
    Das, A.
    Dean, A.
    McNulty, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [18] First-line Nab-paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer from Routine Clinical Practice
    Vogel, Arndt
    Pelzer, Uwe
    Salah-Eddin, Al-Batran
    Koester, Wolf
    IN VIVO, 2014, 28 (06): : 1135 - 1140
  • [19] Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
    Tempero, M.
    Oh, D.
    Macarulla, T.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D.
    Starling, N.
    Bachet, J.
    Chang, H.
    Maurel, J.
    Lonardi, S.
    Coussens, L.
    Fong, L.
    Tsao, L.
    Cole, G., Jr.
    James, D.
    Tebernero, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 126 - 126
  • [20] Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients
    Pecora, I.
    Vivaldi, C.
    Rovesti, G.
    Catanese, S.
    Salani, F.
    Gardini, A. Casadei
    Massa, V.
    Bernardini, L.
    Riggi, M.
    Andrikou, K.
    Rapposelli, I.
    Formica, V.
    Cesario, S.
    Caccese, M.
    Lencioni, M.
    Vasile, E.
    Falcone, A.
    Fornaro, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S151 - S151
12345